Regeneron Stock Drops 060% Trading Volume Plummets 2738% Ranking 70th in Daily Volume

On June 3, 2025, Regeneron Pharmaceuticals (REGN) experienced a significant decline, with its stock price dropping by 0.60%. The trading volume for the day was 10.51 billion, marking a 27.38% decrease from the previous day. This placed Regeneron at the 70th position in terms of trading volume for the day.

Regeneron Pharmaceuticals recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals. This agreement grants Regeneron exclusive clinical development and commercial rights outside of China for HS-20094, a dual GLP-1/GIP receptor agonist currently in Phase 3 testing. The therapeutic candidate has shown promising efficacy and safety data, with a profile similar to the only FDA-approved GLP-1/GIP receptor agonist. Regeneron will make an upfront payment of $80 million to Hansoh, with potential additional payments of up to $1.93 billion for achieving development, regulatory, and sales milestones. Future royalties for global net sales outside of the designated territories would be in the low double digits.

This agreement is part of Regeneron's broader strategy to advance better obesity treatments by enhancing the quality of weight loss. The company is committed to addressing significant unmet needs in obesity management, including sustaining weight loss and maintaining muscle mass over time. The acquisition of HS-20094 will increase the versatility of Regeneron's clinical programs for obesity and accelerate its mission to support quality, sustained weight loss and the associated long-term health benefits.

Regeneron's pipeline focuses on promoting and preserving muscle during weight loss, aiming to increase the amount of fat loss since adiposity is the principal driver of comorbidities and metabolic diseases associated with obesity. The company has an extensive pipeline of agents to address these comorbidities and metabolic diseases, which have the potential to be combined with GLP-1RAs. This positions Regeneron uniquely to make a meaningful difference in obesity and obesity-related diseases.